Senthil Vel Sundaram, Chief Executive Officer at Terns Pharmaceuticals, Inc. (TERN), bought 3 shares at $1.41 ($4) on 2022-11-30, disclosed to the SEC on 2023-02-03.
Open-market purchase of $4 TERN by Chief Executive Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| NITE | SELL | 2019-04-03 | $10K | — | Filing → |
| NITE | SELL | 2019-01-09 | $5K | — | Filing → |